Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

quarterly results

- PMLiVE

Dr Reddy’s brings its generics portfolio to France

Continues the European roll-out of its oncology and anti-infective products

- PMLiVE

GSK’s Witty ends on a high, but warns 2017 looking ‘uncertain’

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Change at the top at Teva as Vigodman departs

CEO replaced ad interim by chairman Yitzhak Peterburg as search begins

AstraZeneca AZ

2017 set to be a “defining year” for AZ

Potential immuno-oncology blockbuster durvalumab leads the charge for AZ’s new launches

Roche Basel Switzerland

Tecentriq growth offsets Avastin’s US decline at Roche

Shifts focus to newer therapies in anticipation of brewing biosimilar competition

Sanofi reception

Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Competition to Roche’s blockbuster RA therapy heats up as Canada is first to licence new drug

- PMLiVE

AbbVie weak on new drug sales, but Humira stays strong

World’s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short

Bristol-Myers Squibb (BMS) building

Opdivo drives growth at BMS, but US sales slow down

Sales beginning to lose momentum despite new indications bringing in $1.3bn for Q4

- PMLiVE

GSK appoints president of global pharmaceuticals

Luke Miels joins from AstraZeneca

Novartis Gehry Building

Novartis ‘reviewing options’ for Alcon division

Possible sale or spin-off in store for eyecare unit as firm reports Q4 operating loss of $132m

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links